

IND OPEN MEETING

FRIDAY APRIL 29, 9:30 AM-11:00 AM

CHAIR : DR. QUINCY CHU
IND PROGRAM DIRECTOR : DR. LESLEY SEYMOUR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To summarize equity, diversity and inclusion considerations in early clinical trials.
- To describe and discuss results of recent Investigational New Drug studies conducted by the CCTG.
- Review treatment strategies for renal cancer

9:30	Welcome	Dr. Quincy Chu
9:35	IND Team Awards announcement	Dr. Quincy Chu
9:40	Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award & Lecture: Novel multi-modal combination strategies for advanced kidney cancer	Dr. Aly Khan Lalani
10:05	IND.228 - A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours	Dr. Abha Gupta
10:13	IND.232 - A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer	Dr. Eric Winqvist
10:22	IND.236 - A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer	Dr. Phil Bedard
10:30	Educational Talk – Equity, Diversity, Inclusion, Indigeneity, and Accessibility (EDIIA)	Jessica Sleeth Pamela Brown-Walker
10:55	Close	Dr. Quincy Chu